Academic Journals Database
Disseminating quality controlled scientific knowledge

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

ADD TO MY LIST
 
Author(s): Sharma Rohini | Graham Janet | Blagden Sarah | Gabra Hani

Journal: BMC Cancer
ISSN 1471-2407

Volume: 11;
Issue: 1;
Start page: 289;
Date: 2011;
Original page

Keywords: ovarian cancer | resistance | chemotherapy | dose-dense | carboplatin | paclitaxel | thrombocytopaenia

ABSTRACT
Abstract Background Platinum agents have shown demonstrable activity in the treatment of patients with platinum resistant, recurrent ovarian cancer when delivered in a "dose-dense" fashion. However, the development of thrombocytopenia limits the weekly administration of carboplatin to no greater than AUC 2. Paclitaxel has a well-described platelet sparing effect however its use to explicitly provide thromboprotection in the context of dose dense carboplatin has not been explored. Methods We treated seven patients with platinum resistant ovarian cancer who had previously received paclitaxel or who had developed significant peripheral neuropathy precluding the use of further full dose weekly paclitaxel. Results We were able to deliver carboplatin AUC 3 and paclitaxel 20 mg/m2 with no thrombocytopenia or worsening of neuropathic side-effects, and with good activity. Conclusions We conclude that this regimen may be feasible and active, and could be formally developed as a "platinum-focussed dose-dense scaffold" into which targeted therapies that reverse platinum resistance can be incorporated, and merits further evaluation.
Why do you need a reservation system?      Save time & money - Smart Internet Solutions